Lilly Asia Ventures leads $90m Series B in clinical-stage biotech firm Regor

Lilly Asia Ventures leads $90m Series B in clinical-stage biotech firm Regor

Eudora Wang

19 February, 2021

biotechLilly Asia VenturesRegor Therapeutics

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter

You may also like

Read more from Greater China

Nikkei Logo
DealStreetAsia Logo
About Us
Team
Advertise
Contact
Careers
Blog
Privacy Policy
Terms & Conditions
© Copyright DEALSTREETASIA 2014-2025 All rights reserved.